Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**L-ornithine l-aspartate** is an ammonia-lowering amino-acid salt composed of L-ornithine and L-aspartate, marketed in certain countries as **Hepa-Merz**. It supports ammonia detoxification through two endogenous pathways: hepatic urea synthesis and glutamine synthesis in liver and peripheral tissues, thereby reducing hyperammonemia that contributes to hepatic encephalopathy. It is supplied as oral granules and as an intravenous infusion concentrate, and is principally used for latent or manifest hepatic encephalopathy associated with impaired liver detoxification, including cirrhosis. ([merztherapeutics.com](https://merztherapeutics.com/science/hepatology/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-ornithine l-aspartate.